VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept
Launched by VANTIA LTD · Aug 20, 2009
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
Dysmenorrhoea is suffered by between 50% and 90% of women of child bearing age. Up to 30% of these women are non-responsive to the currently prescribed therapies. As such it represents an area of unmet medical need. VA111913 inhibits vasopressin-induced contractions of human myometrial strips and human myometrial blood vessels in vitro. By this mechanism, it is anticipated that the pain of dysmenorrhoea, a condition in which myometrial tone and contractions are increased and blood flow to the uterus is decreased compared to normal, may be reduced.
Subjects will be dosed with VA111913 TS an...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women between 18 and 35 years old
- • Not pregnant
- • History of primary dysmenorrhoea
- • Regular menstrual cycles
- • Signed informed consent
- Exclusion Criteria:
- • Known secondary dysmenorrhoea
- • Concomitant use of regular prescription or non prescription medications or herbal remedies
- • Any clinically significant medical history or active disease
- • Participation in another clinical study in the last 3 months
- • Contraindication to chosen rescue medications or allergy to their constituents
- • Other protocol defined eligibility criteria may apply
About Vantia Ltd
Vantia Ltd. is a pioneering clinical trial sponsor dedicated to advancing innovative therapies through rigorous research and development. With a focus on high-quality clinical trials, Vantia Ltd. collaborates with healthcare professionals and institutions to bring cutting-edge treatments to market. The company prioritizes patient safety and scientific integrity, leveraging a team of experienced professionals to ensure compliance with regulatory standards and optimize trial outcomes. Through its commitment to excellence, Vantia Ltd. aims to make a meaningful impact on global health by accelerating the development of novel medical solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Peoria, Arizona, United States
Salt Lake City, Utah, United States
Belfast, , United Kingdom
Austin, Texas, United States
Patients applied
Trial Officials
David Bell
Principal Investigator
Bio-Kinetic Europe Limited
Stephen E Daniels
Principal Investigator
Premier Research Group plc
Vernon Yamashiro
Principal Investigator
Jean Brown Research
Louise Taber
Principal Investigator
Pivotal Research Centers
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials